Remove 2028 Remove Disease Remove Therapies
article thumbnail

WuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

The Pharma Data

A Game-Changing Growth Hormone Therapy Lonapegsomatropin is a long-acting recombinant human growth hormone (rhGH) therapy designed to be administered once weekly. Localized commercial production is anticipated to begin by 2028, following the completion of the technology transfer and necessary scale-up processes.

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Last year, Jakafi brought in nearly $2.8 billion in sales.

Licensing 117
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Competitive Edge of Biosimilars

DrugBank

This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles. billion by 2028. One key challenge is the development of biosimilars for complex biologics, such as monoclonal antibodies used in cancer treatment and gene therapies.

article thumbnail

Inside The Altascientist Issue 33: CNS Drug Development – Integrated Solutions Lessen Complexity

Alta Sciences

Listen or read Issue 33 of The Altascientist on altasciences.com , or wherever you listen to podcasts: GROWING NEEDS FOR CNS THERAPY SOLUTIONS The different parts of the nervous system, including the brain and spinal cord and the peripheral nervous system, are important drug targets for many serious diseases affecting human health.

article thumbnail

2021 Biotech IPOs Get Off to a Roaring Start

The Pharma Data

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. The company is based in Suzhou and Shanghai, China. Ortho Clinical Diagnostics is a leader in in vitro diagnostics.

article thumbnail

Almirall demonstrates resilient performance year to date despite COVID-19 impacts

The Pharma Data

R&D pipeline continues to drive future value through innovation and differentiated therapies including expected upcoming approval of Tirbanibulin. Likewise, we continue to build an R&D pipeline to make a significant difference in patients’ lives by treating a wide range of skin diseases. .

article thumbnail

Article EMA Thank You British regulators tease new device regulations in informative live session

Agency IQ

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. MHRA launched the pilot in late 2023 and ultimately chose eight products with different technologies that address life-threatening diseases with no equivalent solutions that also support the U.K.’s s Life Sciences Vision.